Gregory M Sullivan1, Maria A Oquendo2, Matthew Milak2, Jeffrey M Miller2, Ainsley Burke2, R Todd Ogden3, Ramin V Parsey4, J John Mann5. 1. Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York2Department of Psychiatry, Columbia University, New York, New York3currently with Tonix Pharmaceuticals, LLC, New York, New York. 2. Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York2Department of Psychiatry, Columbia University, New York, New York. 3. Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York2Department of Psychiatry, Columbia University, New York, New York4Department of Biostatistics, Mailman School of Public Health, Columbia University, New York. 4. currently with Department of Psychiatry and Behavioral Science, Stony Brook University School of Medicine, Stony Brook, New York. 5. Division of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York2Department of Psychiatry, Columbia University, New York, New York6Department of Radiology, Columbia University, New York, New York.
Abstract
IMPORTANCE: Serotonergic system dysfunction has been associated with increased lethal suicide attempts and suicide. Dysfunction includes higher binding of serotonin(1A) autoreceptor in the brainstem raphe of individuals who die by suicide. OBJECTIVES: To determine the relationships between brain serotonin(1A) binding and suicidal behavior in vivo in major depressive disorder (MDD) using positron emission tomography and the serotonin(1A) antagonist radiotracer carbon C 11 [11C]-labeled WAY-100635. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional positron emission tomography study at an academic medical center from 1999 through 2009. We compared serotonin(1A) binding between individuals with MDD who did not attempt suicide (nonattempters) (n = 62) and those who attempted suicide (attempters) (n = 29). We subdivided the attempters into those with lower (n = 16) and higher (n = 13) levels of lethality. MAIN OUTCOMES AND MEASURES: The binding potential (BPF) of [11C]WAY-100635 (calculated as the number of receptors available divided by affinity) in the prefrontal cortex (PFC) and brainstem, estimated by kinetic modeling with an arterial input function; the severity of suicidal behaviors, including lethality and intent of suicide attempts; and suicidal ideation. RESULTS: Using a linear mixed-effects model, we found no difference between attempters and nonattempters with MDD in serotonin(1A) BPF in the PFC regions (F1,88 = 0.03; P = .87) or in the raphe nuclei (F1,88 = 0.29; P = .59). Raphe nuclei serotonin(1A) BPF was 45.1% greater in higher-lethality attempters compared with lower-lethality attempters (F1,25 = 7.33; P = .01), whereas no difference was observed in the PFC regions (F1,25 = 0.12; P = .73). Serotonin(1A )BPF in the raphe nuclei of suicide attempters was positively correlated with the lethality rating (F1,25 = 10.56; P = .003) and the subjective lethal intent factor (F1,25 = 10.63; P = .003; R2 = 0.32) based on the most recent suicide attempt. Suicide ideation in participants with MDD was positively correlated with serotonin(1A) BPF in the PFC regions (F1,88 = 5.19; P = .03) and in the raphe nuclei (F1,87 = 7.38; P = .008; R2 = 0.12). CONCLUSIONS AND RELEVANCE: Higher brainstem raphe serotonin(1A)BPF observed in higher-lethality suicide attempters with MDD is in agreement with findings in suicide studies and also with the finding of low cerebrospinal fluid levels of 5-hydroxyindoleacetic acid in higher-lethality suicide attempters. Higher brainstem raphe serotonin(1A) BPF would be consistent with lower levels of serotonin neuron firing and release and supports a model of impaired serotonin signaling in suicide and higher-lethality suicidal behavior. Severity of suicidal ideation in MDD is related to brainstem and prefrontal serotonin(1A) BPF, suggesting a role for both regions in suicidal ideation. Lower levels of serotonin release at key brain projection sites, such as the prefrontal regions, may favor more severe suicidal ideation and higher-lethality suicide attempts.
IMPORTANCE: Serotonergic system dysfunction has been associated with increased lethal suicide attempts and suicide. Dysfunction includes higher binding of serotonin(1A) autoreceptor in the brainstem raphe of individuals who die by suicide. OBJECTIVES: To determine the relationships between brain serotonin(1A) binding and suicidal behavior in vivo in major depressive disorder (MDD) using positron emission tomography and the serotonin(1A) antagonist radiotracer carbon C 11 [11C]-labeled WAY-100635. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional positron emission tomography study at an academic medical center from 1999 through 2009. We compared serotonin(1A) binding between individuals with MDD who did not attempt suicide (nonattempters) (n = 62) and those who attempted suicide (attempters) (n = 29). We subdivided the attempters into those with lower (n = 16) and higher (n = 13) levels of lethality. MAIN OUTCOMES AND MEASURES: The binding potential (BPF) of [11C]WAY-100635 (calculated as the number of receptors available divided by affinity) in the prefrontal cortex (PFC) and brainstem, estimated by kinetic modeling with an arterial input function; the severity of suicidal behaviors, including lethality and intent of suicide attempts; and suicidal ideation. RESULTS: Using a linear mixed-effects model, we found no difference between attempters and nonattempters with MDD in serotonin(1A) BPF in the PFC regions (F1,88 = 0.03; P = .87) or in the raphe nuclei (F1,88 = 0.29; P = .59). Raphe nuclei serotonin(1A) BPF was 45.1% greater in higher-lethality attempters compared with lower-lethality attempters (F1,25 = 7.33; P = .01), whereas no difference was observed in the PFC regions (F1,25 = 0.12; P = .73). Serotonin(1A )BPF in the raphe nuclei of suicide attempters was positively correlated with the lethality rating (F1,25 = 10.56; P = .003) and the subjective lethal intent factor (F1,25 = 10.63; P = .003; R2 = 0.32) based on the most recent suicide attempt. Suicide ideation in participants with MDD was positively correlated with serotonin(1A) BPF in the PFC regions (F1,88 = 5.19; P = .03) and in the raphe nuclei (F1,87 = 7.38; P = .008; R2 = 0.12). CONCLUSIONS AND RELEVANCE: Higher brainstem raphe serotonin(1A)BPF observed in higher-lethality suicide attempters with MDD is in agreement with findings in suicide studies and also with the finding of low cerebrospinal fluid levels of 5-hydroxyindoleacetic acid in higher-lethality suicide attempters. Higher brainstem raphe serotonin(1A) BPF would be consistent with lower levels of serotonin neuron firing and release and supports a model of impaired serotonin signaling in suicide and higher-lethality suicidal behavior. Severity of suicidal ideation in MDD is related to brainstem and prefrontal serotonin(1A) BPF, suggesting a role for both regions in suicidal ideation. Lower levels of serotonin release at key brain projection sites, such as the prefrontal regions, may favor more severe suicidal ideation and higher-lethality suicide attempts.
Authors: Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: J P R Jacobsen; W B Siesser; B D Sachs; S Peterson; M J Cools; V Setola; J H A Folgering; G Flik; M G Caron Journal: Mol Psychiatry Date: 2011-05-03 Impact factor: 15.992
Authors: Ramin V Parsey; R Todd Ogden; Jeffrey M Miller; Adrienne Tin; Natalie Hesselgrave; Ellen Goldstein; Arthur Mikhno; Matthew Milak; Francesca Zanderigo; Gregory M Sullivan; Maria A Oquendo; J John Mann Journal: Biol Psychiatry Date: 2010-05-23 Impact factor: 13.382
Authors: Gregory M Sullivan; Maria A Oquendo; Norman Simpson; Ronald L Van Heertum; J John Mann; Ramin V Parsey Journal: Biol Psychiatry Date: 2005-07-22 Impact factor: 13.382
Authors: Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Maria A Oquendo; Ramin S Hastings; Yung-Yu Huang; Norman Simpson; R Todd Ogden; Xian-Zhang Hu; David Goldman; Victoria Arango; Ronald L Van Heertum; J John Mann; Ramin V Parsey Journal: Arch Gen Psychiatry Date: 2007-02
Authors: Maria A Oquendo; Giovanni P A Placidi; Kevin M Malone; Carl Campbell; John Keilp; Beth Brodsky; Lawrence S Kegeles; Thomas B Cooper; Ramin V Parsey; Ronald L van Heertum; J John Mann Journal: Arch Gen Psychiatry Date: 2003-01
Authors: Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2017-02-01 Impact factor: 4.530
Authors: Honglei Yin; Hanga Galfalvy; Spiro P Pantazatos; Yung-Yu Huang; Gorazd B Rosoklija; Andrew J Dwork; Ainsley Burke; Victoria Arango; Maria A Oquendo; J John Mann Journal: Depress Anxiety Date: 2016-03-31 Impact factor: 6.505
Authors: Faranak Vahid-Ansari; Mireille Daigle; M Chiara Manzini; Kenji F Tanaka; René Hen; Sean D Geddes; Jean-Claude Béïque; Jonathan James; Zul Merali; Paul R Albert Journal: J Neurosci Date: 2017-11-03 Impact factor: 6.167
Authors: Maria A Oquendo; Hanga Galfalvy; Gregory M Sullivan; Jeffrey M Miller; Matthew M Milak; M Elizabeth Sublette; Sebastian Cisneros-Trujillo; Ainsley K Burke; Ramin V Parsey; J John Mann Journal: JAMA Psychiatry Date: 2016-10-01 Impact factor: 21.596